A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy
As a malignant tumor, liver cancer is mainly treated with chemotherapy, while chemotherapeutic drugs, such as doxorubicin (DOX), may lead to toxicity, drug resistance and poor prognosis. The targeted delivery systems of combining natural products and chemotherapeutic drugs are useful to eliminate ca...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1685 |
| _version_ | 1797408382701797376 |
|---|---|
| author | Lixia Chen Jinshuai Lan Zhe Li Ruifeng Zeng Yu Wang Lu Zhen Haojieyin Jin Yue Ding Tong Zhang |
| author_facet | Lixia Chen Jinshuai Lan Zhe Li Ruifeng Zeng Yu Wang Lu Zhen Haojieyin Jin Yue Ding Tong Zhang |
| author_sort | Lixia Chen |
| collection | DOAJ |
| description | As a malignant tumor, liver cancer is mainly treated with chemotherapy, while chemotherapeutic drugs, such as doxorubicin (DOX), may lead to toxicity, drug resistance and poor prognosis. The targeted delivery systems of combining natural products and chemotherapeutic drugs are useful to eliminate cancers with reduced toxicity and increased efficiency. In this study, a diosgenin-based liposome loaded with DOX (Dios-DOX-LP) was developed for synergistic treatment of liver cancer, in which Dios not only replaced cholesterol as the membrane regulator to keep stability of liposomes, but also became the chemotherapy adjuvant of DOX for synergistic treatment. Dios-DOX-LP was characterized by particle size (99.4 ± 6.2 nm), zeta potential (−33.3 ± 2.5 mV), and entrapment efficiency (DOX: 98.77 ± 2.04%, Dios: 87.75 ± 2.93%), which had a good stability and slow-release effect. Compared with commercial DOX liposome (CHOL-DOX-LP), Dios-DOX-LP had an improved anti-tumor effect in vitro and in vivo by inducing the apoptosis and inhibiting the proliferation of the tumor cell, which was 1.6 times better than CHOL-DOX-LP in cytotoxicity, and had 78% of the tumor inhibition rate on tumor-bearing nude mice. Dios-DOX-LP provided a novel idea to achieve synergistic tumor treatment using diosgenin as a liposome material. |
| first_indexed | 2024-03-09T03:57:40Z |
| format | Article |
| id | doaj.art-941b6ec0ceb248778a5d710be4ebec05 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T03:57:40Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-941b6ec0ceb248778a5d710be4ebec052023-12-03T14:17:47ZengMDPI AGPharmaceutics1999-49232022-08-01148168510.3390/pharmaceutics14081685A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer TherapyLixia Chen0Jinshuai Lan1Zhe Li2Ruifeng Zeng3Yu Wang4Lu Zhen5Haojieyin Jin6Yue Ding7Tong Zhang8School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaExperiment Center of Teaching & Learning, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, ChinaAs a malignant tumor, liver cancer is mainly treated with chemotherapy, while chemotherapeutic drugs, such as doxorubicin (DOX), may lead to toxicity, drug resistance and poor prognosis. The targeted delivery systems of combining natural products and chemotherapeutic drugs are useful to eliminate cancers with reduced toxicity and increased efficiency. In this study, a diosgenin-based liposome loaded with DOX (Dios-DOX-LP) was developed for synergistic treatment of liver cancer, in which Dios not only replaced cholesterol as the membrane regulator to keep stability of liposomes, but also became the chemotherapy adjuvant of DOX for synergistic treatment. Dios-DOX-LP was characterized by particle size (99.4 ± 6.2 nm), zeta potential (−33.3 ± 2.5 mV), and entrapment efficiency (DOX: 98.77 ± 2.04%, Dios: 87.75 ± 2.93%), which had a good stability and slow-release effect. Compared with commercial DOX liposome (CHOL-DOX-LP), Dios-DOX-LP had an improved anti-tumor effect in vitro and in vivo by inducing the apoptosis and inhibiting the proliferation of the tumor cell, which was 1.6 times better than CHOL-DOX-LP in cytotoxicity, and had 78% of the tumor inhibition rate on tumor-bearing nude mice. Dios-DOX-LP provided a novel idea to achieve synergistic tumor treatment using diosgenin as a liposome material.https://www.mdpi.com/1999-4923/14/8/1685diosgenindoxorubicinliposomesynergistic treatmentliver cancer |
| spellingShingle | Lixia Chen Jinshuai Lan Zhe Li Ruifeng Zeng Yu Wang Lu Zhen Haojieyin Jin Yue Ding Tong Zhang A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy Pharmaceutics diosgenin doxorubicin liposome synergistic treatment liver cancer |
| title | A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy |
| title_full | A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy |
| title_fullStr | A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy |
| title_full_unstemmed | A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy |
| title_short | A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy |
| title_sort | novel diosgenin based liposome delivery system combined with doxorubicin for liver cancer therapy |
| topic | diosgenin doxorubicin liposome synergistic treatment liver cancer |
| url | https://www.mdpi.com/1999-4923/14/8/1685 |
| work_keys_str_mv | AT lixiachen anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT jinshuailan anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT zheli anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT ruifengzeng anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT yuwang anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT luzhen anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT haojieyinjin anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT yueding anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT tongzhang anoveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT lixiachen noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT jinshuailan noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT zheli noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT ruifengzeng noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT yuwang noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT luzhen noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT haojieyinjin noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT yueding noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy AT tongzhang noveldiosgeninbasedliposomedeliverysystemcombinedwithdoxorubicinforlivercancertherapy |